TransCelerate BioPharma Inc.

TransCelerate BioPharma Inc. is a non-profit organization dedicated to fostering collaboration across the global biopharmaceutical research and development (R&D) community. Its core mission is to identify, prioritize, design, and facilitate the implementation of solutions aimed at driving the efficient, effective, and high-quality delivery of new medicines. Headquartered in West Conshohocken, Pennsylvania, the organization serves as a catalyst for change within the clinical research landscape.

TransCelerate delivers practical solutions designed to simplify clinical trial design and execution, enhance quality, and reduce the administrative burden across the R&D ecosystem. The organization has developed over 570 tools and resources, with initiatives focusing on areas such as transforming connectivity, enabling information sharing and reuse, and promoting innovative trial designs. Key offerings include a GCP Training Mutual Recognition Program, common templates for nonclinical studies, and efforts to enable translational safety and SEND implementation for cross-study analysis.

In recent developments, TransCelerate released its 2024 Annual Report in February 2025, outlining a strategic vision to transform clinical research through its convergence with clinical care. The organization also announced leadership transitions, with Robert Metcalf appointed as Chair of the Board and Christopher Corsico as Vice Chair. Janice Chang serves as the Chief Executive Officer. TransCelerate has expanded its global membership, welcoming Gilead Sciences in early 2024, bringing its consortium to over 20 leading biopharmaceutical innovators, and actively collaborates with more than 18 global health authorities.